Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Targeted Therapy in Oncology.

Literature DB >> 27407885

Targeted Therapy in Oncology.

B K Mishra¹, Purvish M Parikh².

Abstract

Keywords: Oncology; Targeted therapy

Year: 2011 PMID： 27407885 PMCID： PMC4921964 DOI： 10.1016/S0377-1237(06)80063-8

Source DB: PubMed Journal: Med J Armed Forces India ISSN： 0377-1237

Keyword Cloud
References

× No keyword cloud information.

26 in total

1. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

Authors: Charles L Vogel; Melody A Cobleigh; Debu Tripathy; John C Gutheil; Lyndsay N Harris; Louis Fehrenbacher; Dennis J Slamon; Maureen Murphy; William F Novotny; Michael Burchmore; Steven Shak; Stanford J Stewart; Michael Press
Journal: J Clin Oncol Date: 2002-02-01 Impact factor: 44.544

2. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.

Authors: P Feugier; A Van Hoof; C Sebban; P Solal-Celigny; R Bouabdallah; C Fermé; B Christian; E Lepage; H Tilly; F Morschhauser; P Gaulard; G Salles; A Bosly; C Gisselbrecht; F Reyes; B Coiffier
Journal: J Clin Oncol Date: 2005-05-02 Impact factor: 44.544

Review 3. Mylotarg: antibody-targeted chemotherapy comes of age.

Authors: E L Sievers; M Linenberger
Journal: Curr Opin Oncol Date: 2001-11 Impact factor: 3.645

4. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop.

Authors: Sergei Roumiantsev; Neil P Shah; Mercedes E Gorre; John Nicoll; Bradley B Brasher; Charles L Sawyers; Richard A Van Etten
Journal: Proc Natl Acad Sci U S A Date: 2002-07-29 Impact factor: 11.205

Review 5. COX-2 inhibition and lung cancer.

Authors: Alan B Sandler; Steven M Dubinett
Journal: Semin Oncol Date: 2004-04 Impact factor: 4.929

6. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

Authors: Masahiro Fukuoka; Seiji Yano; Giuseppe Giaccone; Tomohide Tamura; Kazuhiko Nakagawa; Jean-Yves Douillard; Yutaka Nishiwaki; Johan Vansteenkiste; Shinzoh Kudoh; Danny Rischin; Richard Eek; Takeshi Horai; Kazumasa Noda; Ichiro Takata; Egbert Smit; Steven Averbuch; Angela Macleod; Andrea Feyereislova; Rui-Ping Dong; José Baselga
Journal: J Clin Oncol Date: 2003-05-14 Impact factor: 44.544

Targeted Therapy in Oncology.

1. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

2. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.

Review 3. Mylotarg: antibody-targeted chemotherapy comes of age.

4. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop.

Review 5. COX-2 inhibition and lung cancer.

6. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

Review 7. Modulation of cellular radiation responses by histone deacetylase inhibitors.

Review 8. CTLA-4: new insights into its biological function and use in tumor immunotherapy.

9. [Treatment of cutaneous T-cell lymphomas with bexarotene].

Review 10. Targeted therapy for metastatic renal cell carcinoma.